Seneca Valley virus based compositions and methods for treating disease
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
1. An isolated nucleic acid comprising a nucleic acid sequence having at least 95% sequence identity to: (i) SEQ ID NO:1 or (ii) a contiguous portion of SEQ ID NO:1 that is at least 200 nucleotides in length.
2. The isolated nucleic acid of claim 1 , wherein the nucleic acid is RNA or DNA.
3. An isolated Seneca Valley virus or derivative or relative thereof, having a genome comprising a sequence that is at least 95% identical to SEQ ID NO:1.
4. The isolated Seneca Valley virus or derivative or relative thereof of claim 3 , further comprising identifying characteristics of ATCC Patent Deposit number PTA-5343, wherein the identifying characteristics are: (i) a single stranded RNA genome (positive (+) sense strand) of about 7.5 or about 7.3 kilobases (kb); (ii) a diameter of about 27 nanometers; (iii) a capsid comprising at least 3 proteins that have molecular weights of about 31 kDa, 36 kDa and 27 kDa; (iv) a buoyant density of approximately 1.34 g/mL on a cesium chloride gradient; and (v) replication competence in tumor cells.
5. The virus of claim 3 comprising the following characteristics: replication competence in tumor cells, tumor-cell tropism, and lack of cytolysis in normal cells.
6. The virus of claim 5 , wherein said virus is replication competent in tumor cell types having neuroendocrine properties.
7. A pharmaceutical composition comprising an effective amount of the virus of any one of claims 4 - 6 and a pharmaceutically acceptable carrier.
8. An isolated Seneca Valley virus having ATCC Patent Deposit Number PTA-5343.
9. A method of killing an abnormally proliferative cell comprising contacting the cell with the virus of any one of claims 4 - 6 .